These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 7303836

  • 1. [Venoruton--used not only in venopathies? Symposium on O-(beta-hydroxyethyl)-rutoside (=Venoruton) in vascular diseases].
    ZFA (Stuttgart); 1981 Sep 20; 57(26):1758-60. PubMed ID: 7303836
    [No Abstract] [Full Text] [Related]

  • 2. [Drug therapy of venopathies].
    Esser W.
    Fortschr Med; 1975 Oct 23; 93(30):1506-7. PubMed ID: 1225812
    [No Abstract] [Full Text] [Related]

  • 3. Anticatatonic effect of venoruton.
    Aley KO, Kulkarni SK.
    Methods Find Exp Clin Pharmacol; 1988 Apr 23; 10(4):263-5. PubMed ID: 2898576
    [Abstract] [Full Text] [Related]

  • 4. [Prevention of cystoid macular edema with O-beta-hydroxyethyl-rutoside (Venoruton) in a double-blind study].
    Artaria LG.
    Klin Monbl Augenheilkd; 1982 Jun 23; 180(6):568-70. PubMed ID: 6752553
    [No Abstract] [Full Text] [Related]

  • 5. [Effect of O-(beta-hydroxyethyl)-rutoside (venoruton) on the adherence of leukocytes in patients with arteriosclerosis obliterans of the lower limbs].
    Lukjan H, Szpak A, Bodzenta A, Bielawiec M, Rosc D, Chyzy R.
    Pol Arch Med Wewn; 1985 Jun 23; 73(6):345-50. PubMed ID: 3880372
    [No Abstract] [Full Text] [Related]

  • 6. [Long-term therapy of retinal vasculopathies with oral administration of high doses of O-(beta-hydroxyethyl)-rutoside].
    Agolini G, Cavallini GM.
    Clin Ter; 1987 Jan 31; 120(2):101-10. PubMed ID: 2972438
    [No Abstract] [Full Text] [Related]

  • 7. Influence of O-(beta-hydroxyethyl)-rutoside or venoruton on lactate dehydrogenase of human cultured varicose veins.
    Matagne D, Hamoir G.
    Biochem Pharmacol; 1975 Aug 15; 24(16):1491-4. PubMed ID: 1191306
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Capillary resistance raising action of Venoruton. Experimental data on the therapeutic effects of Venoruton].
    Gábor M.
    Acta Pharm Hung; 1983 May 15; 53(3):115-20. PubMed ID: 6880764
    [No Abstract] [Full Text] [Related]

  • 10. [Venalot used in therapy of phlebopathies].
    Lacativa AS.
    Med Welt; 1980 May 09; 31(19):727-9. PubMed ID: 7421506
    [No Abstract] [Full Text] [Related]

  • 11. The effect of HR (O-Beta-Hydroxyethylo-Rutoside, Venoruton) on the deformability of erythrocytes in patients with arteriosclerosis obliterans of lower limbs.
    Lukjan H, Rość D, Chyzy R, Bodzenta A, Szpak A.
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1985 May 09; 112(1):191-6. PubMed ID: 2581865
    [Abstract] [Full Text] [Related]

  • 12. [Treatment of sudden deafness of vascular etiology with venoruton].
    Madej S.
    Otolaryngol Pol; 1989 May 09; 43(3):214-7. PubMed ID: 2695884
    [Abstract] [Full Text] [Related]

  • 13. [Efficacy of troxerutin on the flow properties of blood under defined conditions of circulation. A double-blind study of patients with diabetic retinopathy and arteriosclerotic retinopathy].
    Gallasch G, Dörfer C, Schmitt T, Stage A.
    Klin Monbl Augenheilkd; 1985 Jul 09; 187(1):30-5. PubMed ID: 3906246
    [Abstract] [Full Text] [Related]

  • 14. Effect of tri- and tetra-O-(beta-hydroxyethyl)-rutoside on red blood cell aggregation of human blood.
    van Haeringen NJ.
    Bibl Anat; 1975 Jul 09; 13():197-9. PubMed ID: 1231726
    [No Abstract] [Full Text] [Related]

  • 15. Venoruton in the therapy of central retinal vein occlusion.
    Zygulska-Mach H, Kostka-Trabka E, Kielar J, Grodzinska L, Dieron K, Kedzior A.
    Ther Hung; 1985 Jul 09; 33(2):79-82. PubMed ID: 3842005
    [No Abstract] [Full Text] [Related]

  • 16. Metabolism of hydroxyethylrutosides (HR): metabolism of [14C]-HR in man.
    Hackett AM, Griffiths LA, Luyckx AS, van Cauwenberge H.
    Arzneimittelforschung; 1976 Jul 09; 26(5):925-8. PubMed ID: 989368
    [Abstract] [Full Text] [Related]

  • 17. Effect of Venoruton on the factor XIII activity in rat plasma.
    Grochal M, Sempińska-Edelberg E, Plewiński J.
    Pol J Pharmacol Pharm; 1978 Jul 09; 30(5):659-63. PubMed ID: 751007
    [Abstract] [Full Text] [Related]

  • 18. The effect of O-(beta-hydroxyethyl)-rutoside (HR) on macromolecular leakage, thrombosis and haemostasis in experimental animals.
    Bergqvist D, Svensjö E, Arfors KE.
    Ups J Med Sci; 1978 Jul 09; 83(2):123-7. PubMed ID: 664118
    [Abstract] [Full Text] [Related]

  • 19. Venoruton as a radioprotector: a haematological assessment.
    Kanwar KC, Shukla VK, Verma A.
    Radiobiol Radiother (Berl); 1990 Jul 09; 31(6):517-22. PubMed ID: 2101456
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of O-(beta-hydroxyethyl)-rutosides at high dosage in counteracting the unwanted activity of oral contraceptives on venous function.
    Cappelli R, Pecchi S, Oberhauser V, Forconi S, Di Perri T.
    Int J Clin Pharmacol Res; 1987 Jul 09; 7(4):291-9. PubMed ID: 3596872
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.